NCT06357338

Brief Summary

Retrospective observational study to evaluate c-MYC expression in non invasive and invasive mammry carcinoma

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Mar 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 19, 2024

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

April 5, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 10, 2024

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2026

Completed
Last Updated

April 10, 2024

Status Verified

April 1, 2024

Enrollment Period

1 year

First QC Date

April 5, 2024

Last Update Submit

April 5, 2024

Conditions

Invasive Breast Cancer

Outcome Measures

Primary Outcomes (1)

  • role of c-MYC in breast cancer

    difference between expression of c-MYC in non invasive and invasive mammary carcinoma

    1 year

Study Arms (2)

non invasive mammary carcinoma

35 cases with non invasive breast cancer with low and high nuclear grades and co existing microfoci of invasion

Other: no intervention

invasive mammary carcinoma

35 cases of invasive breast cancer undergone MRM and classify them according grading, staging and luminal subtypes

Other: no intervention

Interventions

no interventionOTHER

No intervention

invasive mammary carcinomanon invasive mammary carcinoma

Eligibility Criteria

Age15 Years+
Sexfemale
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

women with breast lumps administered to oncology center

You may qualify if:

  • Specimens of Modified Radical Mastectomies from breast carcinoma patients

You may not qualify if:

  • Cases with insufficient clinical data.
  • Tissue blocks of destroyed or insufficient material, unfit for diagnosis.
  • Cases who received pre-operative chemotherapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag university

Sohag, Egypt

Location

Related Publications (1)

  • Gao FY, Li XT, Xu K, Wang RT, Guan XX. c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment. Cell Commun Signal. 2023 Jan 31;21(1):28. doi: 10.1186/s12964-023-01043-1.

    PMID: 36721232BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

formalin fixed, paraffin embedded tissue blocks of cases of mammary carcinoma

Study Officials

  • Afaf Alnashar, professor

    Sohag University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
resident doctor of pathologu

Study Record Dates

First Submitted

April 5, 2024

First Posted

April 10, 2024

Study Start

March 19, 2024

Primary Completion

April 1, 2025

Study Completion

April 1, 2026

Last Updated

April 10, 2024

Record last verified: 2024-04

Locations

EG(1)